SBC Medical lacks Nasdaq-required independent directors after Sayama leaves board
SBC Medical received a Nasdaq notice that it no longer meets independent director and audit committee rules after Mike Sayama chose not to seek re-election. Stockholders also approved charter amendments and the board adopted amended bylaws, including a majority-vote resignation policy for uncontested director elections. The company says the notice has no immediate effect on its listing, but it must restore compliance within the cure period.
Key points
- Nasdaq notice received July 10, 2026; board has four members, two of them independent, and the audit committee has two independent directors
- Cure period ends at the earlier of the next annual meeting or July 9, 2027, or January 5, 2027 if the next annual meeting is held before that date
- Restated charter effective July 9, 2026; amended and restated bylaws adopted July 8, 2026
- Stockholders elected four directors and ratified MaloneBailey, LLP as auditor for fiscal 2026 with 93,954,650 votes for
The filing
Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 14, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.